Research map: A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing

Back to the article

Papers in this map

  1. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary · David N. Louis · 2021 · 12624 citations · Cited by this paper
  2. Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Riddhi A. Babel · 2026 · Related
  3. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival · Michel Lacroix · 2001 · 3121 citations · Cited by this paper
  4. Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · 2026 · Related
  5. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood · Michael Weller · 2020 · 2073 citations · Cited by this paper
  6. Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · 2026 · Related
  7. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019 · Quinn T. Ostrom · 2022 · 1602 citations · Cited by this paper
  8. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · 2026 · Related
  9. Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials · W.J. Curran · 1993 · 1318 citations · Cited by this paper
  10. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · 2026 · Related
  11. Multicollinearity in Regression Analyses Conducted in Epidemiologic Studies · Kristina P. Vatcheva · 2016 · 1317 citations · Cited by this paper
  12. IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · 2026 · Related
  13. Association of the Extent of Resection With Survival in Glioblastoma · Timothy J. Brown · 2016 · 1114 citations · Cited by this paper
  14. Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · 2026 · Related
  15. Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma · Annette M. Molinaro · 2020 · 669 citations · Cited by this paper
  16. Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · 2026 · Related
  17. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 · Thierry Gorlia · 2007 · 565 citations · Cited by this paper
  18. A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · 2026 · Related
  19. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017–2021 · Mackenzie Price · 2024 · 512 citations · Cited by this paper
  20. Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary · 2026 · Related
  21. Alternatives to P value: confidence interval and effect size · Dong Kyu Lee · 2016 · 487 citations · Cited by this paper
  22. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma · Bryan D. Choi · 2024 · 449 citations · Cited by this paper
  23. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group · Philipp Karschnia · 2022 · 387 citations · Cited by this paper
  24. Immunotherapy for glioblastoma: current state, challenges, and future perspectives · Yang Liu · 2024 · 335 citations · Cited by this paper
  25. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma · Lakshmi Nayak · 2020 · 268 citations · Cited by this paper
  26. Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma · Jing Li · 2010 · 239 citations · Cited by this paper
  27. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma · Maryam Rahman · 2016 · 234 citations · Cited by this paper
  28. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States · Quinn T. Ostrom · 2022 · 105 citations · Cited by this paper
  29. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group · Philipp Karschnia · 2023 · 102 citations · Cited by this paper
  30. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution · Signe Regner Michaelsen · 2013 · 87 citations · Cited by this paper
  31. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419) · Caroline Hertler · 2023 · 82 citations · Cited by this paper
  32. Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis · Ruth P. Norris · 2020 · 64 citations · Cited by this paper
  33. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series · Nicola Montemurro · 2021 · 52 citations · Cited by this paper
  34. Clinical Prediction Models: A Practical Approach to Development, Validation and Updating by STEYERBERG, E. W. · Rumana Omar · 2010 · 51 citations · Cited by this paper
  35. Depression and anxiety in glioma patients · Pim B. van der Meer · 2023 · 51 citations · Cited by this paper
  36. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status · Chan Woo Wee · 2017 · 46 citations · Cited by this paper
  37. Unlocking the health system barriers to maximise the uptake and utilisation of molecular diagnostics in low-income and middle-income country setting · Nyanda Elias Ntinginya · 2021 · 42 citations · Cited by this paper
  38. Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study · Jae Yeoul Ryu · 2019 · 36 citations · Cited by this paper
  39. Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma · Nayan Lamba · 2020 · 31 citations · Cited by this paper

Source: OpenAlex (CC0)